The Functional Assessment of Cancer Therapy-Prostate (FACT-P) Scales in Men with Prostate Cancer: Reliability and Validity of the Korean Version by Hong, Jeong Hee et al.
J Korean Med Sci 2006; 21: 295-9
ISSN 1011-8934
INTRODUCTION
Prostate cancer is the sixth most common malignancy in
Korean men. It accounts for approximately 3% of all newly
diagnosed cases of cancer patients among men. The incidence
of prostate cancer has significantly increased during the past
decade (1). 
Men who are newly diagnosed with prostate cancer receive
various treatment modalities based on the stage of disease.
Since prostate cancer is characterized by slowly growing tu-
mors, and is usually diagnosed in elderly males, individual
health-related quality of life (HRQOL) is an increasingly
important consideration with respect to treatment (2).
Cella and colleagues (3) developed the Functional Assess-
ment of Cancer Therapy-General (FACT-G). It has a well-
established validity and reliability (3-6), and has been widely
used to measure the HRQOL in cancer patients. However,
since the FACT-G has included comprehensive and general
HRQOL items, disease-specific subscales of the FACT have
been introduced. Subsequently, the development and valida-
tion of a prostate cancer subscale have been described (7, 8).
Thus, the Functional Assessment of Cancer Therapy-Prostate
(FACT-P) consists of FACT-G and a prostate cancer subscale.
The Korean FACT-G had been previously translated (access
http://www.facit.org for details) and validated (6, 9, 10). How-
ever, the prostate cancer subscale had not been translated
into Korean. Therefore, we present the results of a study that
was performed to translate and validate the Korean FACT-P
questionnaire.
MATERIALS AND METHODS
Development of the Korean FACT-P
The Korean version of the FACT-P was developed from
the English FACT-P, which was provided by the Center on
Outcomes, Research and Education (CORE), at Evanston
Northwestern Healthcare (Evanston, IL, U.S.A.). The initial
procedure was a double back-translation of the prostate can-
cer subscale, according to a previously described method (11),
which was performed in the following sequence. Step 1: for-
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The Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Scales in Men with Prostate Cancer: Reliability and Validity of the
Korean Version
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire
is a relevant, worldwide tool used for assessing the health-related quality of life in
men with prostate cancer. The purpose of this study was to translate the FACT-P
into Korean, to assess its reliability and validity, and to test its discriminative ability
between the cancer patients and normal controls. The Korean version was devel-
oped via the FACT multilingual translation project. The translated questionnaire was
self-administered to 70 prostate cancer patients and 70 age-matched controls. In
evaluating its psychometric properties for cancer patients, internal consistency and
test-retest reliability were used. Validity was estimated by using inter-subscale cor-
relations and discriminant validity between cancer patients and controls. Cronbach’s
alpha coefficient for the individual subscales were 0.7 or greater (range 0.73 to 0.89),
except for emotional well-being (0.61). The test-retest reliability showed high cor-
relations (intraclass coefficients ranged from 0.72 to 0.93). Inter-subscale correla-
tions demonstrated each subscale was unrelated, but moderate correlation was
observed between social/family well-being and functional well-being subscales
(r=0.56). The FACT-P scale could discriminate reliably between the cancer patients
and controls in most subscales. In conclusion, the Korean version of the FACT-P
is a reliable and valid questionnaire in patients with prostate cancer.
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ward translations by two native Korean translators. Step 2:
reconciliation of the forward translations by another native
Korean translator, who was not involved in step 1. Step 3:
back-translation of the reconciled version by a native English
speaker, who was also fluent in Korean. Step 4: independent
reviews by 3 bilingual experts, which included two experts
with knowledge of medical concepts and one language coor-
dinator, who completed the most suitable translation for each
item from the forward or reconciled forms and/or provided
alternative translations if necessary. Step 5: finalization by the
Functional Assessment of Chronic Illness Therapy (FACIT)
translations project team. Step 6: formatting and proofread-
ing of the new translation for pilot testing on native Koreans
who were prostate cancer patients.
The revised Korean version was tested on 15 Korean
prostate cancer patients at the Samsung Medical Center, in
Seoul. The purpose of this pre-test was to determine whether
any items were difficult to understand or culturally irrelevant.
All comments made by the patients regarding comprehen-
sion of each item were recorded. There was no item to which
they felt uneasy responding. The final Korean FACT-P (Ver-
sion 4) was then completed, following statistical confirma-
tion by the FACIT translations project team. 
Testing of reliability and validity 
A total of 70 consecutive prostate cancer patients, who
underwent curative or palliative treatment, were identified
as the cohort of a validation test in an outpatient setting. In
addition, an equal number of age-matched controls were
selected to compare with the results of the FACT-P in the
cancer patients. The data from the controls were obtained
when they visited either the Center for Health Promotion
or the outpatient center of the Department of Urology at
Samsung Medical Center. The exclusion criteria for the con-
trols were: a previous, or current, history of another malig-
nancy; age less than 50 yr old; serum level of prostate-spe-
cific antigen (PSA) ≥2.5 ng/mL; and/or a chronic debilitat-
ing disease. Our institutional research ethics board approved
the study protocol. All the subjects provided their fully in-
formed consents. 
To estimate test-retest reliability, the Korean FACT-P ques-
tionnaire was administered twice to each cancer patient after
an interval of one week. After each patient submitted the
first questionnaire in an outpatient center, a second question-
naire was submitted by mail. 
Statistical analyses
The statistical analyses for the reliability and validity of
the FACT-P were performed using SPSS for Windows (Ver-
sion 10.0; SPSS, Chicago, IL, U.S.A.). The internal consis-
tency of each subscale was estimated by using Cronbach’s
alpha coefficient. The test-retest reliability was estimated
by calculating intraclass correlation coefficients of the sub-
scales between the initial and subsequent measured question-
naires.
Construct validity was estimated from the inter-subscale
correlation by using Spearman’s correlation. The differences
between the FACT-P scores of the cancer patients and the
controls were calculated by Student t-test and Wilcoxon rank-
sum test. 
RESULTS
A descriptive analysis of the baseline characteristics of the
cancer patients is demonstrated in Table 1. The median time
following a diagnosis of cancer was 23 months (range, 2-115
months). More than 98% of the patients had a favorable per-
formance status rating in our study. 
The age distribution between the cancer patients and the
controls was similar, with an average age of 66.1 and 64.5 yr
old, respectively (p=0.160). The mean PSA value in the con-
trols was 1.2±0.5 ng/mL. The controls completed the ques-
tionnaires either in the Center for Health Promotion (23 men,
33%) or the outpatient center of the Department of Uro-
logy (47 men, 67%).
The mean scores of the FACT-P subscale, along with Cron-
bach’s alpha coefficients, are presented in Table 2. In addition,
the English FACT-P scores are detailed. Cronbach’s alpha
coefficients for the individual subscales were 0.7 or greater,
except for emotional well-being. Internal consistency of the
FACT-G and FACT-P totals was both high. Cronbach’s alpha
coefficient for the FACT-G, was 0.86, and for the FACT-P,
was 0.88. 
Table 3 demonstrates that test-retest reliability was high
for physical well-being, functional well-being, FACT-G,
prostate cancer subscale, trial outcome index, and the FACT-
ECOG, Eastern Cooperative Oncology Group; HIFU, High Intensity Fo-
cused Ultrasound.
Characteristic No. of patients (%)
Age (yr)
Mean±standard deviation (range) 66.1±6.3 (51-80)
50-59 11 (15.7)
60-69 35 (50.0)
≥70 24 (34.3)
ECOG performance status
0: normal activity without symptoms 39 (55.7)
1: some symptoms, ambulatory 30 (42.9)
2: confined to bed (<50% of waking day) 1 (1.4)
Extent of disease
Non-metastatic prostate cancer 40 (57.1)
Metastatic prostate cancer  30 (42.9)
Treatment
Curative (surgery, radiation therapy, HIFU therapy) 32 (45.7)
Palliative (hormonal ablation therapy) 38 (54.3)
Table 1. Baseline characteristics of the cancer patients (n=70)P total (intraclass correlation coefficients were greater than
0.80). Moderately high correlations were observed for emo-
tional well-being and social/family well-being (with coeffi-
cients of 0.72 and 0.74). 
Table 4 demonstrates the inter-subscale correlations. It has
been hypothesized that a correlation coefficient greater than
0.40 between subscales, indicated that the two were concep-
tually related (12). In the FACT-G subscales, the highest
correlation was observed between social/family well-being
and functional well-being subscales, but the correlation was
modest (r=0.56). The other correlations were less than 0.4,
inferring that each subscale of the FACT-G was unrelated.
However, other high correlations were observed not only
between the prostate cancer subscale and physical well-being
(r=0.64), but also between the prostate cancer subscale and
functional well-being (r=0.45). The reason was that the pro-
state cancer subscale had some degree of overlapping items
compared with the other subscales, especially in the case of
physical well-being. 
The ability of the FACT-P scale to discriminate reliably
between the cancer patients and the age-matched controls
was assessed by comparing the responses from the two groups.
Table 5 demonstrates that highly significant differences were
observed between the cancer patients and the controls for
most subscales. The least degree of difference between the
cancer patients and the controls was observed with emotional
well-being, where the results failed to reach statistical signifi-
cance. There were significant differences between the cancer
patients and the controls in half (20 items) of the total 39
items. The cancer patients usually suffered from pain, erec-
tile dysfunction, distress, and dissatisfaction. 
DISCUSSION
Men, with either localized or advanced prostate cancer, face
a range of treatment options associated with disturbing side
effects and functional impairments (13). Although the pri-
mary endpoint of treatment for prostate cancer remains to
eliminate disease progression and maximize survival, HRQOL
is recognized increasingly as an important outcome of any
treatment modality (2, 13, 14). In fact, the incidence of pro-
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Data are presented as mean±SD.
Subscale Test Retest
Intraclass correlation
coefficient (95% CI)
PWB 24.0±5.1 24.1±5.8 0.80 (0.67, 0.88)
SFWB 15.9±6.2 14.9±5.7 0.74 (0.57, 0.84)
EWB 18.2±3.9 17.9±4.0 0.72 (0.55, 0.83)
FWB 18.6±5.7 18.7±6.0 0.91 (0.84, 0.95)
FACT-G 76.6±14.0 75.7±14.6 0.91 (0.85, 0.95)
PCS 31.6±7.0 32.5±7.5 0.88 (0.79, 0.93)
TOI 74.2±14.1 75.30±16.0 0.92 (0.85, 0.95)
FACT-P total  108.2±19.1 108.2±20.5 0.93 (0.88, 0.96)
Table 3. Test-retest reliability of the Korean FACT-P using intra-
class correlation coefficients (n=47)
The value of Spearman’s correlation greater than 0.40 between sub-
scales indicates they are meaningfully related.
*p<0.05, 
� p<0.01.
Subscale
FACT-G
PWB SFWB EWB FWB
PCS
PWB 1.00
SFWB 0.01 1.00
EWB 0.22 0.29* 1.00
FWB 0.25* 0.56
� 0.36
� 1.00
PCS 0.64
� 0.28* 0.39
� 0.45
� 1.00
Table 4. Inter-subscale correlations 
Subscale
Patients (n=70)
Mean SD
p value
Controls (n=70)
Mean SD
PWB 23.7 (4.6) 25.9 (2.2) 0.011*
SFWB 15.3 (6.4) 16.8 (5.2) 0.044*
EWB 17.7 (3.8) 18.2 (3.3) 0.601*
FWB 18.0 (6.1) 20.2 (4.4) 0.014*
FACT-G 74.6 (14.0) 81.1 (10.1) 0.001*
PCS 30.3 (7.2) 37.2 (5.8) <0.001*
TOI 72.0 (13.9) 83.4 (10.0) <0.001
�
FACT-P total  104.9 (19.2) 118.3 (13.6) <0.001
�
Table 5. Discriminant validity for Korean FACT-P subscales bet-
ween the cancer patients and the age-matched controls
*Wilcoxon rank-sum test, 
� Student t-test.
*The data of patients with prostate cancer were reported by Esper et al.
(7). The mean scores and Cronbach’s alpha coefficient in the English
FACT-P were obtained from the patients with different disease status
who participated in the bi-center survey. 
� FACT-P (Version 3).
PWB, physical well-being; SFWB, social/family well-being; EWB, emo-
tional well-being; FWB, functional well-being; PCS, prostate cancer
subscale; TOI (PWB+FWB+PCS), trial outcome index; SD, standard
deviation;  , Cronbach’s alpha coefficient. 
Subscale
Korean FACT-P
Mean SD
English FACT-P*
Mean SD
English FACT-P*
Mean SD
PWB (7 items) 23.7 4.6 0.77 21.2 5.3 0.77 26.2 2.8 0.64
SFWB (7 items) 15.3 6.4 0.82 22.1 4.9 0.69 23.5 4.3 0.71
EWB (6 items) 17.7 3.8 0.61
EWB (5 items)
� 14.6 4.2 0.74 15.5 4.2 0.75
FWB (7 items) 18.0 6.1 0.89 16.5 6.6 0.82 21.6 5.2 0.83
FACT-G (27 items) 74.6 14.0 0.86
FACT-G (28 items)
� 82.1 14.1 0.85 93.6 11.7 0.87
PCS (12 items) 30.3 7.2 0.73 27.6 6.8 0.65 36.9 6.6 0.69
TOI (26 items) 72.0 13.9 0.86 65.2 16.4 0.90 84.6 11.7 0.85
FACT-P total  104.9 19.2 0.88
(39 items)
FACT-P total 109.8 19.1 0.87 130.5 16.3 0.89
(40 items)
�
Table 2. Internal consistency of the Korean version of the Func-
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state cancer has dramatically increased during the past decade
in Korea. However, no prostate cancer-specific HRQOL mea-
surement had previously been developed and validated in a
clinical setting.
There are many questionnaires available to measure the
HRQOL of patients with prostate cancer (2). The FACIT
questionnaires are among those more commonly used for
various cancers and chronic illnesses in research settings. The
FACIT are an expansion of the familiar FACT questionnaires
into other chronic illnesses and conditions. 
The FACT-G (Version 4) contains a 27-item questionnaire
and is composed of four subscales of HRQOL: physical well-
being (PWB), social/family well-being (SFWB), emotional
well-being (EWB), and functional well-being (FWB) (6, 15).
The prostate cancer subscale (PCS) is composed of a 12-item
issue, related to prostate-specific questions, which include
sexuality, bowel/bladder function, and pain. Equivalent ver-
sions of the FACT-P questionnaires are available in 20 dif-
ferent languages, which permit cross-cultural comparisons
of people from diverse backgrounds (6). Therefore, the FACT-
P questionnaire is considered to be a relevant measurement
for assessing the health-related quality of life in men with
prostate cancer.
This study described the method used to translate and vali-
date the FACT-P from its original English language into
Korean. 
Generally, the customary ranges of Cronbach’s alpha coef-
ficient are identified as acceptable (0.60 to 0.69), good (0.70
to 0.79), and high (0.80 to 1.0) levels. The translated Kore-
an-language version appeared to perform at least as well as
the original English form, with comparable reliability coef-
ficients (7). With the exception of the emotional well-being
subscale (Cronbach’s alpha coefficient=0.61), internal con-
sistency coefficients were all greater than 0.70. The item
GE2, I am satisfied with how I am coping with my illness,
showed significantly low inter-item correlation in the emo-
tional well-being subscale. The translated term for ‘coping’
is not commonly used in community basis. About 34% of
patients are more than 70 yr old and 14% were not gradu-
ated from middle school in this study. Therefore, they might
have a problem for understanding the meaning of coping.
Test-retest repeatability correlation coefficients ranged from
0.72 to 0.93, and were all highly significant. Overall, the
FACT-P demonstrated a strong internal consistency, mea-
sured in terms of both the total scale and individual domain
scores, and adequate test-retest reliability.
The inter-subscale correlations demonstrated that there
was a modest relationship between social/family well-being
and functional well-being subscales in this study. This result
may be due to a unique characteristic of the enrolled patients.
That is, since almost of the cancer patients in this study had
a favorable performance status, they were not likely to have
been disturbed by the disease itself. Therefore, the function-
al status of these patients was good, and they were able to
perform their social roles in their relationships with friends
and families. 
For the discriminant validity test, analyses were performed
in each of these areas in two separate samples of the cancer
patients and the age-matched controls. The differences bet-
ween the two groups were significant for all subscales, with
the exception of emotional well-being. Therefore, the FACT-P
questionnaire can reliably differentiate between the cancer
patients and the controls in the clinical practice.
The relatively small sample sizes and selection of cancer
patients are recognized limitations of this study. Our cancer
cohort is exclusively interviewed in outpatient setting, and
thus patients with good performance status were participat-
ed in this study. Therefore, our results may not represent
the characteristics of whole prostate cancer patients in Korea.
Thus, further studies are needed with large sampled popu-
lations and various performance statuses. 
In conclusion, the Korean translation of the FACT-P ques-
tionnaire was developed and verified in its reliability and
validity. This instrument can be used as a reliable self-admin-
istrated scale for assessing HRQOL in patients with prostate
cancer in both the clinical and research fields.
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